Sydney, Australia

Tommy Chung Yeung Chui

This inventor holds 8 USPTO granted patents and 2 published patent applications and 8 EPO patents. Top assignee: Resmed Pty Ltd. Active years: 2020-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tommy Chung Yeung Chui. Retrieved from https://idiyas.com/inventor/tommy-chung-yeung-chui

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 100.0

 

Average Co-Inventor Count = 23.0

ph-index = 4

Forward Citations = 40(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Tommy Chung Yeung Chui - Innovative Inventor from Sydney

Introduction: Tommy Chung Yeung Chui is a renowned inventor based in Sydney, Australia, known for his groundbreaking contributions to various industries.

Latest Patents: Tommy Chung Yeung Chui holds several patents in the fields of technology and healthcare, with his most recent inventions focusing on sustainable energy solutions and medical devices.

Career Highlights: With a career spanning over two decades, Tommy Chung Yeung Chui has established himself as a leading figure in the innovation landscape, with numerous successful inventions that have had a significant impact on society.

Collaborations: Throughout his career, Tommy Chung Yeung Chui has collaborated with top research institutions, universities, and companies to bring his inventions to life, showcasing his ability to work effectively in multidisciplinary teams.

Conclusion: Tommy Chung Yeung Chui's passion for innovation and his dedication to creating solutions for real-world problems have solidified his reputation as a visionary inventor in Sydney and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…